219 related articles for article (PubMed ID: 11595068)
1. Safety of an ofloxacin-based antitubercular regimen for the treatment of tuberculosis in patients with underlying chronic liver disease: a preliminary report.
Saigal S; Agarwal SR; Nandeesh HP; Sarin SK
J Gastroenterol Hepatol; 2001 Sep; 16(9):1028-32. PubMed ID: 11595068
[TBL] [Abstract][Full Text] [Related]
2. [Effectiveness and problems of PZA-containing 6-month regimen for the treatment of new pulmonary tuberculosis patients].
Wada M
Kekkaku; 2001 Jan; 76(1):33-43. PubMed ID: 11211781
[TBL] [Abstract][Full Text] [Related]
3. Recurrent Drug-Induced Hepatitis in Tuberculosis-Comparison of Two Drug Regimens.
Shamaei M; Mirsaeidi M; Baghaei P; Mosaei H; Marjani M; Tabarsi P
Am J Ther; 2017; 24(2):e144-e149. PubMed ID: 26057141
[TBL] [Abstract][Full Text] [Related]
4. The management of anti-tuberculosis drug-induced hepatotoxicity.
Tahaoğlu K; Ataç G; Sevim T; Tärün T; Yazicioğlu O; Horzum G; Gemci I; Ongel A; Kapakli N; Aksoy E
Int J Tuberc Lung Dis; 2001 Jan; 5(1):65-9. PubMed ID: 11263519
[TBL] [Abstract][Full Text] [Related]
5. Controlled trial of 4 three-times-weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis. Second report: the results up to 24 months. Hong Kong Chest Service/British Medical Research Council.
Tubercle; 1982 Jun; 63(2):89-98. PubMed ID: 6758252
[TBL] [Abstract][Full Text] [Related]
6. Protective effect of N-acetylcysteine on antituberculosis drug-induced hepatotoxicity.
Baniasadi S; Eftekhari P; Tabarsi P; Fahimi F; Raoufy MR; Masjedi MR; Velayati AA
Eur J Gastroenterol Hepatol; 2010 Oct; 22(10):1235-8. PubMed ID: 20461008
[TBL] [Abstract][Full Text] [Related]
7. Hepatotoxicity of anti-tuberculosis chemotherapy in patients with liver cirrhosis.
Shin HJ; Lee HS; Kim YI; Lim SC; Jung JP; Ko YC; Kwon YS
Int J Tuberc Lung Dis; 2014 Mar; 18(3):347-51. PubMed ID: 24670574
[TBL] [Abstract][Full Text] [Related]
8. Hepatotoxicity of antitubercular treatments. Rationale for monitoring liver status.
Durand F; Jebrak G; Pessayre D; Fournier M; Bernuau J
Drug Saf; 1996 Dec; 15(6):394-405. PubMed ID: 8968694
[TBL] [Abstract][Full Text] [Related]
9. [The effectiveness of pyrazinamide-containing six-month short course chemotherapy].
Wada M
Kekkaku; 2000 Nov; 75(11):665-73. PubMed ID: 11140090
[TBL] [Abstract][Full Text] [Related]
10. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial.
Jasmer RM; Saukkonen JJ; Blumberg HM; Daley CL; Bernardo J; Vittinghoff E; King MD; Kawamura LM; Hopewell PC;
Ann Intern Med; 2002 Oct; 137(8):640-7. PubMed ID: 12379063
[TBL] [Abstract][Full Text] [Related]
11. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
API Consensus Expert Committee
J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
[TBL] [Abstract][Full Text] [Related]
12. Management of and risk factors related to hepatotoxicity during tuberculosis treatment.
Babalık A; Arda H; Bakırcı N; Ağca S; Oruç K; Kızıltaş S; Cetintaş G; Calışır HC
Tuberk Toraks; 2012; 60(2):136-44. PubMed ID: 22779934
[TBL] [Abstract][Full Text] [Related]
13. Liver injury during antituberculosis treatment: an 11-year study.
Døssing M; Wilcke JT; Askgaard DS; Nybo B
Tuber Lung Dis; 1996 Aug; 77(4):335-40. PubMed ID: 8796249
[TBL] [Abstract][Full Text] [Related]
14. [Six-months chemotherapy (2HRZS or E/4HRE) of new cases of pulmonary tuberculosis--six year experiences on its effectiveness, toxicity, and acceptability].
Wada M; Yoshiyama T; Ogata H; Ito K; Mizutani S; Sugita H
Kekkaku; 1999 Apr; 74(4):353-60. PubMed ID: 10355221
[TBL] [Abstract][Full Text] [Related]
15. Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy.
Lee BH; Koh WJ; Choi MS; Suh GY; Chung MP; Kim H; Kwon OJ
Chest; 2005 Apr; 127(4):1304-11. PubMed ID: 15821209
[TBL] [Abstract][Full Text] [Related]
16. Pyrazinamide and rifampin vs isoniazid for the treatment of latent tuberculosis: improved completion rates but more hepatotoxicity.
McNeill L; Allen M; Estrada C; Cook P
Chest; 2003 Jan; 123(1):102-6. PubMed ID: 12527609
[TBL] [Abstract][Full Text] [Related]
17. A prospective clinical study of isoniazid-rifampicin-pyrazinamide-induced liver injury in an area endemic for hepatitis B.
Hwang SJ; Wu JC; Lee CN; Yen FS; Lu CL; Lin TP; Lee SD
J Gastroenterol Hepatol; 1997 Jan; 12(1):87-91. PubMed ID: 9076631
[TBL] [Abstract][Full Text] [Related]
18. Split-drug regimens for the treatment of patients with sputum smear-positive pulmonary tuberculosis--a unique approach.
Santha T; Rehman F; Mitchison DA; Sarma GR; Reetha AM; Prabhaker R;
Trop Med Int Health; 2004 May; 9(5):551-8. PubMed ID: 15117298
[TBL] [Abstract][Full Text] [Related]
19. A controlled clinical trial of oral short-course regimens in the treatment of sputum-positive pulmonary tuberculosis. Tuberculosis Research Centre.
Int J Tuberc Lung Dis; 1997 Dec; 1(6):509-17. PubMed ID: 9487448
[TBL] [Abstract][Full Text] [Related]
20. [Drug-induced hepatotoxicity caused by anti-tuberculosis drugs in tuberculosis patients complicated with chronic hepatitis].
Kaneko Y; Nagayama N; Kawabe Y; Shimada M; Suzuki J; Kunogi M; Matsui Y; Kawashima M; Suzuki J; Ariga H; Oshima N; Masuda K; Matsui H; Nagai H; Tamura A; Akagawa S; Toyoda E; Machida K; Kurashima A; Yotsumoto H
Kekkaku; 2008 Jan; 83(1):13-9. PubMed ID: 18283910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
